12 March 2015

Responding to the decision to keep everolimus (Afinitor) and eribulin (Halaven) on the Cancer Drugs Fund after an appeal from Novartis and Eisai Samia al Qadhi Chief Executive at Breast Cancer Care says:


“After a worrying few months it will be an enormous relief for people living with secondary breast cancer which is incurable to hear that life-extending drugs everolimus (Afinitor) and eribulin (Halaven) will remain on the Cancer Drugs Fund.


“However it is unacceptable that so many

patients had to go through this period of uncertainty and live with the fear that the drugs they so desperately need would be out of reach. While others will still be denied the chance of improved quality of life as effective treatments for a range of other cancers are still being removed from the Fund today.


“This entire process shows that the Cancer Drugs Fund is on rocky ground and a long-term sustainable system must be found. This can’t be delayed any longer it needs to happen now.”




For further information please contact:

Sheryl Plant Press Manager Breast Cancer Care

020 7960 3532 (out of hours 07702 901 334)



Notes to editors

Spokespeople and case studies available upon request.


About Breast Cancer Care

Breast Cancer Care is the only specialist breast cancer support charity working throughout the UK. We were founded in 1973 by Betty Westgate who was herself diagnosed with breast cancer. In the ensuing forty years we have supported millions of women and their families through our face-to-face phone and online services. We also provide training support and networking opportunities to specialist breast cancer nurses and Breast Cancer Care publications are used by the majority of breast cancer units throughout the UK. We campaign for better support and care and promote the importance of early detection involving people with breast cancer in all that we do. Visit breastcancernow.org or call our free Helpline on 0808 800 6000.